In Stents, How the Mighty are Falling--Fast
It's no surprise that Johnson & Johnson no longer owns the stent market. What's surprising is how fast it lost it.
You may also be interested in...
The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.
The regulatory tools are for use in medical device development.
The US agency plans to hold a virtual workshop that will use breakout sessions to get stakeholder feedback on specific hurdles preventing more pediatric devices coming to market.